Belite Bio (DB:D01) - Stock Price, News & Analysis

D01 Stock Overview

A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. More details

D01 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 67.5% below our estimate of its fair value

Earnings are forecast to grow 69.37% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the German market

Belite Bio, Inc Competitors

Dermapharm Holding

XTRA:DMP

€2.0b

Bayer

XTRA:BAYN

€18.6b

PharmaSGP Holding

XTRA:PSG

€304.6m

MPH Health Care

DB:93M1

€105.3m

Price History & Performance

Summary of all time highs, changes and price drops for Belite Bio
Historical stock prices
Current Share Price	US$60.50
52 Week High	US$81.00
52 Week Low	US$29.50
Beta	-1.6
11 Month Change	-1.63%
3 Month Change	38.13%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	52.59%

Recent updates

Shareholder Returns

	D01	DE Pharmaceuticals	DE Market
7D	-21.9%	1.4%	0.8%
1Y	n/a	-18.4%	9.1%

Return vs Industry: Insufficient data to determine how D01 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how D01 performed against the German Market.

Price Volatility

Is D01's price volatile compared to industry and market?
D01 volatility
D01 Average Weekly Movement	9.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: D01's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: D01's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2016	20	Tom Lin	www.belitebio.com

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.

Belite Bio, Inc Fundamentals Summary

How do Belite Bio's earnings and revenue compare to its market cap?
D01 fundamental statistics
Market cap	€2.22b
Earnings (TTM)	-€31.53m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-59.8x

P/E Ratio

Is D01 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
D01 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$33.03m
Earnings	-US$33.03m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.07
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did D01 perform over the long term?

See historical performance and comparison

Belite Bio DB:D01 Stock Report